Breast Cancer HER2 Equivocal Cases: Is There an Alternative to FISH Testing? A Pilot Study Using Two Different Antibodies Sequentially

被引:0
作者
Yosepovich, Ady [1 ]
Avivi, Camila [1 ]
Bar, Jair [2 ]
Polak-Charcon, Sylvie [1 ]
Mardoukh, Corine [1 ]
Barshack, Iris [1 ]
机构
[1] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Dept Oncol, IL-52621 Tel Hashomer, Israel
来源
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2010年 / 12卷 / 06期
关键词
HER2; breast cancer; immunohistochemistry; fluorescence in situ hybridization; rabbit monoclonal antibody; MONOCLONAL-ANTIBODY; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; CHEMOTHERAPY; TRASTUZUMAB; EFFICACY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: HER2 is an important prognostic and predictive marker in invasive breast cancer. It is currently assessed by immunohistochemistry for protein over-expression and by fluorescence in situ hybridization for gene amplification. The immunohistochemistry-equivocal cases (2+) are currently retested by FISH to determine eligibility for trastuzumab treatment. Retesting by FISH significantly raises the cost of patient management and sometimes delays treatment. The 4B5 is a new, FDA-approved, rabbit monoclonal antibody for HER2 testing. Objectives: To examine the reliability of 4B5 IHC HER2 testing in cases found by CB11 IHC to be HER2 status equivocal. Methods: Twenty-eight invasive breast cancer cases, with an equivocal HER2 status by CB11 IHC, were retested by the 4B5 antibody as well as by FISH analysis. The scoring was performed using the same guidelines as HercepTest and was correlated with the FISH ratio. Results: Of the original 28 CB11 clone designated equivocal cases, 14(50%) showed negative HER2 staining using the 4B5 clone (HercepTest score 0 and 1+). Five cases (18%) proved to be positive (HercepTest score 3+) and 9 cases (32%) remained equivocal (HercepTest score 2+). The corresponding FISH ratio results showed that all 4B5 negative cases were negative by FISH testing, with a negative predictive value of 100%; 4 of 5 of the 4B5-positive cases were positive by FISH testing, with a positive predictive value of 80%. One 4B5-positive case was borderline-high (2.2 ratio) by FISH. The correlation between 485 IHC and FISH was statistically significant (P=0.0013) by chi-square test. Conclusions: Sequential testing by 4B5 IHC could greatly reduce the need for FISH testing in cases considered HER2 equivocal by CB11 IHC. IMAJ 2010; 12: 353-356
引用
收藏
页码:353 / 356
页数:4
相关论文
共 50 条
[41]   Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients [J].
Afzal, Muhammad ;
Amir, Mohammed ;
Hassan, Muhammad Jawad ;
Hussain, Muhammad Sikander ;
Aziz, Muhammad Naveed ;
Murad, Sheeba ;
Murtaza, Iram ;
Anees, Mariam ;
Sultan, Aneesa .
TUMOR BIOLOGY, 2016, 37 (07) :8665-8672
[42]   HER2 gene amplification in patients with breast cancer with equivocal IHC results [J].
Meijer, Sybren L. ;
Wesseling, Jelle ;
Smit, Vincent T. ;
Nederlof, Petra M. ;
Hooijer, Gerrit K. J. ;
Ruijter, Henrique ;
Arends, Jan Willem ;
Kliffen, Mike ;
van Gorp, Joost M. ;
Sterk, Lotus ;
van de Vijver, Marc J. .
JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (12) :1069-1072
[43]   HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category [J].
Holzschuh, Maria-Anna ;
Czyz, Zbigniew ;
Hauke, Sven ;
Inwald, Elisabeth C. ;
Polzer, Bernhard ;
Brockhoff, Gero .
HISTOPATHOLOGY, 2017, 71 (04) :610-625
[44]   High Concordance Between Two Companion Diagnostics Tests A Concordance Study Between the HercepTest and the HER2 FISH pharmDx Kit [J].
Jorgensen, Jan Trost ;
Moller, Susanne ;
Rasmussen, Birgitte B. ;
Winther, Henrik ;
Schonau, Andreas ;
Knoop, Ann .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (01) :145-151
[45]   Assessing the Discordance Rate Between Local and Central HER2 Testing in Women With Locally Determined HER2-Negative Breast Cancer [J].
Kaufman, Peter A. ;
Bloom, Kenneth J. ;
Burris, Howard ;
Gralow, Julie R. ;
Mayer, Musa ;
Pegram, Mark ;
Rugo, Hope S. ;
Swain, Sandra M. ;
Yardley, Denise A. ;
Chau, Miu ;
Lalla, Deepa ;
Yoo, Bongin ;
Brammer, Melissa G. ;
Vogel, Charles L. .
CANCER, 2014, 120 (17) :2657-2664
[46]   Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer [J].
Farshid, Gelareh .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (08) :767-769
[47]   The Knowns and the Unknowns in HER2 Testing in Breast Cancer [J].
Gown, Allen M. ;
Goldstein, Lynn C. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (01) :5-6
[48]   A testing algorithm for determination of HER2 status in patients with breast cancer [J].
Nichols, DW ;
Wolff, DJ ;
Self, S ;
Metcalf, JS ;
Jacobs, D ;
Kneuper-Hall, R ;
Cate, JC .
ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2002, 32 (01) :3-11
[49]   Current issues in ER and HER2 testing by IHC in breast cancer [J].
Gown, Allen M. .
MODERN PATHOLOGY, 2008, 21 :S8-S15
[50]   What Causes Discrepancies in HER2 Testing for Breast Cancer? A Japanese Ring Study in Conjunction With the Global Standard [J].
Umemura, Shinobu ;
Osamura, R. Yoshiyuki ;
Akiyama, Futoshi ;
Honma, Keiichi ;
Kurosumi, Masafumi ;
Sasano, Hironobu ;
Toyoshima, Satoshi ;
Tsuda, Hitoshi ;
Rueschoff, Josef ;
Sakamoto, Goi .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (06) :883-891